Evonik Stock EVK.DE
Evonik stock (EVK.DE): Quarterly and annual results since 2023 from Quarterly Report and IR documents: revenue, earnings, balance sheet, cash flow and management guidance, every figure with its source. As of 08/2026, quarterly reporting. Stock analysis by NadirAlpha. Revenue Q2 2026: EUR 3.9 billion (+11% year on year). Latest reported (Q2 2026): ROCE, Leverage, Cash Conversion Rate. Latest reading: Revenue accelerating, Guidance raised, Strategic pivot.
Revenue accelerating Guidance raised strategy: Strategic pivot
The new quarter, monitored by AI. · NadirAlpha follows every stock through its original filings: the latest figures against their history, guidance against actuals; neutral, continuously updated, every figure clickable with its source.
AI-generated report · not investment advice · figures extracted automatically; please verify against the linked original more
AI-generatedCreated with AI assistance from the company's linked original filings (transparency per Art. 50 EU AI Act). More about the tool: Claude Code.
Not investment adviceNeutral financial information, no recommendation, no investment research within the meaning of MiFID II.
Verify yourselfFigures are extracted automatically, errors are possible. Every figure is clickable with its source; the issuer's original documents are always authoritative.
EditorialThe texts (business model, current status, development and others) are written AI-editorially from the original reports alone, cross-checked automatically and backed with sources; the company's own account, no assessment of our own. Methodology
AI research · This page works as a source-backed data basis for further research with AI assistants such as Claude; every figure remains verifiable via the source links.
Advertisement
Business Model#
What the company does and how it earns its money; written AI-editorially, exclusively from the company's original reports, without any assessment of our own. Methodology
Evonik Industries AG is a German specialty chemicals company that develops and manufactures chemical products and solutions for a broad range of industrial end markets, including nutrition, animal health, coatings, adhesives, personal care, automotive, and electronics. Revenue is generated primarily through the sale of specialty chemical intermediates, additives, and performance materials, organized into business segments including Specialty Additives and Advanced Technologies. Evonik's earnings are shaped by volume, pricing, and product mix dynamics across its portfolio, with performance driven by end-market demand cycles, raw material input costs, and production efficiency across a global manufacturing network. The company pursues structural cost reduction through its ongoing Evonik Tailor Made efficiency program while directing investment toward higher-value specialty applications.
Advertisement
Current Status#
Summary of the most recent reporting period: core figures, drivers and management statements; written editorially from the current original report, every figure backed by a source number. Methodology
Assessment by NadirAlpha, as of Q2 2026.
Evonik reported Q2 2026 sales of 3,893 million, an increase of 11% year-over-year driven by both higher volumes and prices 29. Adjusted EBITDA reached €630 million, up 24% year-over-year, exceeding expectations primarily due to strong Advanced Technologies segment performance 29 31. Adjusted EPS came in at 0.65 137. Following the strong quarter, Evonik raised its FY 2026 adjusted EBITDA outlook considerably to €2.0-2.2 billion from prior guidance of €1.7-2.0 billion 29 31.
Management commentary on the 2024-Q1 results (IR-Quarter, 2024-06-25):
“Sequential earnings improvement despite ongoing challenging environment” Christian Kullmann, Chief Executive Officer 6
Revenue · 2026-Q23,893€m+11.3 % vs. 2025-Q2
Net profit · 2026-Q285€m−31.5 % vs. 2025-Q2
EPS · 2026-Q20.18€−30.8 % vs. 2025-Q2
Revenue trend
Guidance
For FY2026, the company guides Revenue ~15,000 €m (raised); Tax rate ~25% (cut); EBITDA (adjusted) 2,000 to 2,200 €m (raised). 29
ProfitabilityOperating income for Q2 2026 was 163 million and net income reached 85 million 137. Adjusted EBITDA margin expanded to 16.2% in Q2 2026 from 14.5% in Q2 2025 29. Free cash flow improved significantly to 49 million in Q2 2026 compared to -211 million in Q2 2025, supported by better earnings and reduced bonus payouts 31.
LeverageNet debt stood at 4,075 million at the end of Q2 2026, with cash of 390 million 137. Net debt increased compared to year-end 2025 levels, primarily due to dividend payments in the period 31. Net working capital remained elevated at 19.3% of sales, above the company's long-term average of 16% 22.
Management viewFY 2026 sales guidance was raised to around €15 billion from the prior range of €13.5-14.5 billion, reflecting improved market conditions and operational performance 31. ROCE is expected to improve to 7.8% in FY 2026 from 6.1% in FY 2025 33. FY 2026 free cash flow is estimated at €782 million, compared to 695 million in FY 2025 33.
ChangeEvonik extended its Evonik Tailor Made efficiency program through 2029 with an additional 3,200 FTEs targeted for reduction, aiming for tangible financial impact 29 31. The adjusted tax rate guidance for FY 2026 was revised to around 25% from the long-term sustainable level of approximately 30%, reflecting a higher share of earnings generated in lower-tax countries 31. Competitive intensity in the Crosslinkers business continued to create margin pressure mainly in EMEA and Asia, while the Oxeno C4 business faced weak demand conditions that significantly reduced segment earnings 22.
Risks (current)Weak demand and structural headwinds continue to present ongoing market challenges 31. Continued high competitive intensity in the Crosslinkers business is creating margin pressure in EMEA and Asia 22, and fixed cost increases of approximately 4% on a fixed cost base of roughly €5 billion are difficult to compensate during a demand downturn 25. The geopolitical situation in the Middle East has benefited margins in the Oxeno C4 business through higher pricing, while the Additives business is partly supported by war-related supply chain disruptions affecting customer availability, introducing sensitivity to any change in those conditions 31.
New this reporting periodEvonik completed the Oxeno backward integration in Mobile during Q2 2026, representing an acquisition step within the Oxeno business area 31. Planned closures of the Witten and Hanau sites were announced as part of portfolio and footprint restructuring 31. The transfer of the Polyolefins business to a consolidated site was also announced as a planned restructuring step 31.
Advertisement
Price & Chart#
Interactive price chart (TradingView) and the trend of key figures from the core tables. Methodology
Daily candles with news and earnings markers. Loads only on click.
Advertisement · affiliate links; we may earn a commissionAffiliate partnerships help us keep these reports free and regularly updated.
Advertisement
Share-Price Drivers#
Factors the company itself names as material for its business development (IR-based); reproduced neutrally, no price forecast and no assessment of our own. Methodology
Earnings and margin recovery across the refocused specialty-chemicals portfolio
Operating income turned positive at 163 million in Q2 2026 (revenue 3,893 million, net income 85 million, adjusted EPS 0.65), after several quarters of negative operating income, and management guidance was raised, 137
Operating income turned positive at 163 million in Q2 2026 (revenue 3,893 million, net income 85 million, adjusted EPS 0.65), after several quarters of negative operating income, and management guidance was raised, 137
Specialty Additives
Highest-margin unit, reported at a 21.8% margin with revenue of 923 million and growth of 1% year-on-year, 19
Highest-margin unit, reported at a 21.8% margin with revenue of 923 million and growth of 1% year-on-year, 19
Nutrition & Care (incl. Care biosurfactants and animal-nutrition methionine)
Revenue of 1,007 million with growth of 12% year-on-year and a 19.6% margin; Care margin reported at 17%, 19 28; first world-scale biosurfactants plant inaugurated May 2024, a product line gaining traction, 14
Revenue of 1,007 million with growth of 12% year-on-year and a 19.6% margin; Care margin reported at 17%, 19 28; first world-scale biosurfactants plant inaugurated May 2024, a product line gaining traction, 14
Advanced Technologies and Custom Solutions (post-restructuring segments)
Advanced Technologies margin 17% and Custom Solutions margin 17% under the new segment structure, 33
Advanced Technologies margin 17% and Custom Solutions margin 17% under the new segment structure, 33
Alkoxides capacity in Singapore (catalysts for PET recycling and biodiesel)
Carbon-neutral alkoxides plant in Singapore launched August 2025, adding capacity, 24
Carbon-neutral alkoxides plant in Singapore launched August 2025, adding capacity, 24
Smart Materials / Inorganics capacity build-out
Smart Materials revenue 1,098 million at broadly flat growth (0%) with a 13.6% margin; aluminium oxide (AEROXIDE) plant expansion in Yokkaichi, Japan launched October 2025, 19 25
Smart Materials revenue 1,098 million at broadly flat growth (0%) with a 13.6% margin; aluminium oxide (AEROXIDE) plant expansion in Yokkaichi, Japan launched October 2025, 19 25
Infrastructure / Other (SYNEQT carve-out and Oxeno)
Infrastructure carve-out SYNEQT planned for January 2026 and Oxeno backward integration in Mobile completed Q2 2026, reshaping the non-core base, 24 31
Infrastructure carve-out SYNEQT planned for January 2026 and Oxeno backward integration in Mobile completed Q2 2026, reshaping the non-core base, 24 31
Performance Materials
Lower-margin commodity unit reported at a 3.4% margin with revenue of 557 million declining 10% year-on-year, 16
Lower-margin commodity unit reported at a 3.4% margin with revenue of 557 million declining 10% year-on-year, 16
Sector trend: Specialty-chemicals demand and profitability are improving, with Q2 2026 operating income returning to positive territory at 163 million and management raising guidance, 137. Margins diverge sharply by portfolio, with specialty units such as Specialty Additives at 21.8% against commodity-like Performance Materials at 3.4%, 19 16.
Advertisement
Event Timeline#
This timeline collects the material events from the original reports: guidance changes, revenue and margin signals, strategy shifts, product and M&A announcements. Methodology
Overview: one dot per event · click jumps to the period
2026 · 5 events
2026-Q2 · Apr to Jun 2026
Revenue accelerating 2026-08-04
Q2 sales increased 11% to 3,893 million, driven by higher volumes and prices 29
Q2 sales increased 11% to 3,893 million, driven by higher volumes and prices 29
Guidance raised 2026-08-04
FY 2026 adjusted EBITDA outlook raised considerably to €2.0-2.2 billion from prior guidance of €1.7-2.0 billion 29
FY 2026 adjusted EBITDA outlook raised considerably to €2.0-2.2 billion from prior guidance of €1.7-2.0 billion 29
Strategic pivot 2026-08-04
Efficiency programme Evonik Tailor Made extended through 2029 with additional 3,200 FTEs targeted for reduction 29
Efficiency programme Evonik Tailor Made extended through 2029 with additional 3,200 FTEs targeted for reduction 29
2025 · 13 events
2025-Q4 · Oct to Dec 2025
earnings 2026-03-04
Revised 2025 earnings outlook achieved with full-year adjusted EBITDA of €1,874 million 25
Revised 2025 earnings outlook achieved with full-year adjusted EBITDA of €1,874 million 25
earnings 2026-03-04
Q4 free cash flow of 411 million driven by decisive net working capital management 25
Q4 free cash flow of 411 million driven by decisive net working capital management 25
Guidance initiated 2026-03-04
FY2026 adjusted EBITDA guidance initiated at €1.7-2.0 billion, aiming for broadly stable earnings 25
FY2026 adjusted EBITDA guidance initiated at €1.7-2.0 billion, aiming for broadly stable earnings 25
2025-Q3 · Jul to Sep 2025
earnings 2025-11-04
Oxeno C4 business impairment charge of €170 million recorded in Q3, calculated using trough earnings assumptions 24
Oxeno C4 business impairment charge of €170 million recorded in Q3, calculated using trough earnings assumptions 24
Margin compressing 2025-11-04
Adjusted EBITDA margin compressed to 13.2% in Q3 2025 from 15.1% in Q3 2024 24
Adjusted EBITDA margin compressed to 13.2% in Q3 2025 from 15.1% in Q3 2024 24
Guidance cut 2025-11-04
FY2025 adjusted EBITDA guidance cut to approximately €1.9 billion from the €2.0-2.3 billion range, reflecting tougher market conditions 24
FY2025 adjusted EBITDA guidance cut to approximately €1.9 billion from the €2.0-2.3 billion range, reflecting tougher market conditions 24
2025-Q2 · Apr to Jun 2025
earnings 2025-08-01
Q2 adjusted EBITDA declined 12% year-over-year to €509 million, impacted by weaker USD, low consumer confidence, and weakness in Oxeno C4 business 21
Q2 adjusted EBITDA declined 12% year-over-year to €509 million, impacted by weaker USD, low consumer confidence, and weakness in Oxeno C4 business 21
Free cash flow turned negative 2025-08-01
Q2 free cash flow turned negative at 211 million, burdened by higher bonus payouts and temporary net working capital buildup 22
Q2 free cash flow turned negative at 211 million, burdened by higher bonus payouts and temporary net working capital buildup 22
Guidance cut 2025-08-01
FY2025 sales guidance reduced to €14-15 billion from previously €15-17 billion 21
FY2025 sales guidance reduced to €14-15 billion from previously €15-17 billion 21
2025-Q1 · Jan to Mar 2025
Adjusted result turned positive 2025-05-12
Adjusted EBITDA grew 7% year-over-year to €560 million in Q1 2025, with all three divisions showing positive volume growth 18
Adjusted EBITDA grew 7% year-over-year to €560 million in Q1 2025, with all three divisions showing positive volume growth 18
Margin expanding 2025-05-12
Adjusted EBITDA margin expanded 100 basis points year-over-year to 14.8% in Q1 2025 18
Adjusted EBITDA margin expanded 100 basis points year-over-year to 14.8% in Q1 2025 18
2024 · 16 events
2024-Q4 · Oct to Dec 2024
Adjusted result turned positive ◦ 2025-03-05
FY 2024 adj. EBITDA increased 25% year-over-year to €2,065 million with broad-based growth across all divisions 17
FY 2024 adj. EBITDA increased 25% year-over-year to €2,065 million with broad-based growth across all divisions 17
Strategic pivot 2025-03-05
New two-segment group structure with Custom Solutions and Advanced Technologies announced, effective Q2 2025 17
New two-segment group structure with Custom Solutions and Advanced Technologies announced, effective Q2 2025 17
2024-Q3 · Jul to Sep 2024
New market 2024-11-06
New Innovation Growth Areas revealed with €1.5 billion additional sales target by 2032 15
New Innovation Growth Areas revealed with €1.5 billion additional sales target by 2032 15
2024-Q2 · Apr to Jun 2024
Guidance raised 2024-08-01
FY 2024 adj. EBITDA guidance materially lifted by €200 million to the €1.9 to 2.2 billion range 13
FY 2024 adj. EBITDA guidance materially lifted by €200 million to the €1.9 to 2.2 billion range 13
Cash flow inflection 2024-08-01
Operating cash flow reached EUR 360.0 million vs EUR 34.0 million in 2023-Q2 (×10.6). 126
Operating cash flow reached EUR 360.0 million vs EUR 34.0 million in 2023-Q2 (×10.6). 126
2024-Q1 · Jan to Mar 2024
“We are making progress with the planned restructuring of our portfolio. In 2023, we found a new owner for our site in Lülsdorf (Germany): International Chemical Investors Group, which is investing significantly at the site. We are also at an advanced stage in the sale of our Superabsorbents business. When it has been completed, we will have achieved two of the three steps in the disposal of the businesses in our Performance Materials division. Preparations for the sale of the C4 chemicals business are making good headway.” Christian Kullmann, Chairman of the Executive Board 9
earnings 2024-05-08
Adj. EBITDA increased 28% year-over-year to €522 million, driven by Nutrition & Care and Specialty Additives 10
Adj. EBITDA increased 28% year-over-year to €522 million, driven by Nutrition & Care and Specialty Additives 10
Operating income turned positive 2024-05-08
Operating income turned positive for the first time after 3 negative periods (-51.0 to +EUR 252.0 million). 124
Operating income turned positive for the first time after 3 negative periods (-51.0 to +EUR 252.0 million). 124
Strategic pivot 2024-05-08
Evonik Tailor Made reorganization program launched with €400 million savings target 10
Evonik Tailor Made reorganization program launched with €400 million savings target 10
Divestiture 2024-05-08
Divestment of Superabsorbers business signed on March 1, 2024, closing expected mid-year 10
Divestment of Superabsorbers business signed on March 1, 2024, closing expected mid-year 10
Net income turned negative ◦ 2024-02-26
Net loss of EUR 452 million versus net income of €540m in 2022, driven by impairment losses of €736m on assets primarily from restructuring and portfolio optimization 9
Net loss of EUR 452 million versus net income of €540m in 2022, driven by impairment losses of €736m on assets primarily from restructuring and portfolio optimization 9
Revenue decelerating ◦ 2024-02-26
Group sales fell 17% to EUR 15,267 million due to lower volumes, a slight drop in selling prices, and negative currency effects 9
Group sales fell 17% to EUR 15,267 million due to lower volumes, a slight drop in selling prices, and negative currency effects 9
Guidance initiated 2024-02-26
FY2024 adj. EBITDA guidance initiated at €1.7 to 2.0bn; sales forecast set at €15 to 17bn; ROCE expected to be significantly higher than the 2023 level of 3.4% 9
FY2024 adj. EBITDA guidance initiated at €1.7 to 2.0bn; sales forecast set at €15 to 17bn; ROCE expected to be significantly higher than the 2023 level of 3.4% 9
2023 · 12 events
2023-Q4 · Oct to Dec 2023
earnings 2024-03-04
Q4 adj. EBITDA declined 24% yoy; adj. EPS turned negative at -0.12 as full-year adj. EBITDA of €1,656m finished within guidance range despite €50m in exceptional headwinds 8
Q4 adj. EBITDA declined 24% yoy; adj. EPS turned negative at -0.12 as full-year adj. EBITDA of €1,656m finished within guidance range despite €50m in exceptional headwinds 8
Strategic pivot 2024-03-04
Evonik Tailor Made reorganization launched in October targeting €400m in savings by end-2026 through a reduction of up to 2,000 employees 8
Evonik Tailor Made reorganization launched in October targeting €400m in savings by end-2026 through a reduction of up to 2,000 employees 8
Divestiture 2024-03-04
Sale of Superabsorber business signed as the next step in Performance Materials divestment program 8
Sale of Superabsorber business signed as the next step in Performance Materials divestment program 8
2023-Q3 · Jul to Sep 2023
Margin expanding 2023-11-07
Adj. EBITDA margin increased 30 basis points to 12.9% driven by successful pricing policy, ramp-up of contingency measures, and bonus provision release 5
Adj. EBITDA margin increased 30 basis points to 12.9% driven by successful pricing policy, ramp-up of contingency measures, and bonus provision release 5
Guidance confirmed 2023-11-07
FY2023 adj. EBITDA outlook of €1.6 to 1.8bn confirmed; contingency measures extended into 2024 5
FY2023 adj. EBITDA outlook of €1.6 to 1.8bn confirmed; contingency measures extended into 2024 5
Strategic pivot 2023-11-07
Strategic realignment of Technology & Infrastructure division announced to focus resources on three growth divisions, with implementation from mid-2024 to end-2025 5
Strategic realignment of Technology & Infrastructure division announced to focus resources on three growth divisions, with implementation from mid-2024 to end-2025 5
2023-Q2 · Apr to Jun 2023
Net income turned negative ◦ 2023-08-10
Asset impairments of €390m recognized, €305m on Animal Nutrition facilities and €84m on Silica assets, driving net loss of EUR 266 million in Q2 3
Asset impairments of €390m recognized, €305m on Animal Nutrition facilities and €84m on Silica assets, driving net loss of EUR 266 million in Q2 3
Revenue decelerating 2023-08-10
Q2 sales declined 19% yoy to EUR 3,886 million with volumes negative across all divisions except Nutrition & Care 3
Q2 sales declined 19% yoy to EUR 3,886 million with volumes negative across all divisions except Nutrition & Care 3
Guidance cut 2023-08-10
FY2023 adj. EBITDA outlook cut to €1.6-1.8bn from €2.1-2.4bn and sales outlook revised to €14-16bn, no longer assuming any H2 recovery 3
FY2023 adj. EBITDA outlook cut to €1.6-1.8bn from €2.1-2.4bn and sales outlook revised to €14-16bn, no longer assuming any H2 recovery 3
2023-Q1 · Jan to Mar 2023
Strategic pivot 2024-06-25
€250m company-wide cost savings program announced; Animal Nutrition restructured into two separate operating models targeting €200m in savings by 2025 2
€250m company-wide cost savings program announced; Animal Nutrition restructured into two separate operating models targeting €200m in savings by 2025 2
Adjusted result turned negative ◦ 2023-05-09
Q1 adj. EBITDA declined 44% yoy to €409m on 14% volume declines and low plant utilization across all divisions 1
Q1 adj. EBITDA declined 44% yoy to €409m on 14% volume declines and low plant utilization across all divisions 1
Guidance confirmed 2023-05-09
FY2023 adj. EBITDA guidance of €2.1-2.4bn confirmed but lower end of the range considered more likely 1
FY2023 adj. EBITDA guidance of €2.1-2.4bn confirmed but lower end of the range considered more likely 1
Advertisement
Key Figures (€m)#
The company's core financial figures in three views, one below the other: fiscal years (as reported; after restatements the table shows the most recent filing version, marked), half-years (6-month basis, H2 = second half on its own) and quarters (3-month basis, not cumulative). All values are extracted automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original. Methodology
All figures serve only to support your own investment decision and are not a recommendation; the company's original reports are authoritative.
Revenue (€m) · annual basis, as reported
Net income (€m) · annual basis, as reported
EPS (€) · annual basis, as reported
Operating cash flow (€m) · annual basis, as reported
Revenue (€m) · quarterly basis, as reported
Net income (€m) · quarterly basis, as reported
EPS (€) · quarterly basis, as reported
Operating cash flow (€m) · quarterly basis, as reported
Cash (€m) · annual basis, as reported
Debt (€m) · annual basis, as reported
Net Debt (€m) · annual basis, as reported
Capex (€m) · annual basis, as reported
FCF (€m) · annual basis, as reported
D&A (€m) · annual basis, as reported
Cash (€m) · quarterly basis, as reported
Debt (€m) · quarterly basis, as reported
Net Debt (€m) · quarterly basis, as reported
Capex (€m) · quarterly basis, as reported
FCF (€m) · quarterly basis, as reported
D&A (€m) · quarterly basis, as reported
Shown: the most recent fiscal years. Full history since FY2022 is on record.
Fiscal years
Amounts in €m · EPS in € per share · as reported
| Period | Revenue | Op. income | Net income | EPS (€) | EPS adj. (€) | EBITDA (adj.) | OCF | Source |
|---|---|---|---|---|---|---|---|---|
| FY2025 | 14,069 | -420~EBIT | 277~ | 0.57 | 1.36 | 1,874 | 1,443 | 25 |
| FY2024 | 15,157 | 577EBIT | 240~ | 0.48 | 1.66 | 2,065 | 1,713 | 17 |
| FY2023 | 15,267 | -243~EBIT | -452~ | -1.00 | 0.79 | 1,656 | 1,594 | 9 |
Quarters
Amounts in €m · EPS in € per share · as reported
| Period | Published | Revenue | Op. income | Net income | EPS (€) | EPS adj. (€) | EBITDA (adj.) | FCF | Cash | Net Debt | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-Q2* | 2026-08-04 | 3,893 | 163EBIT | 85 | 0.18 | 0.65 | 630 | 49 | 390 | 4,075 | 137 |
| 2026-Q1* | 2026-05-07 | 3,427 | -48~EBIT | 129~ | 0.27 | 0.34 | 475 | 183 | 589 | 3,566 | 27 |
| 2025-Q4* | 2026-03-04 | 3,403 | -66~EBIT | 20~ | 0.04 | 0.15 | 357 | 411 | 495 | 3,670 | 25 |
| 2025-Q3* | 2025-11-03 | 3,391 | -25EBIT | -102~ | -0.23 | 0.27 | 448 | 300 | 454 | 4,039 | 30 |
| 2025-Q2* | 2025-08-01 | 3,499 | -90~EBIT | 124~ | 0.26 | 0.34 | 509 | -211 | 379 | 4,422 | 21 |
| 2025-Q1* | 2025-05-09 | 3,777 | -54~EBIT | 236 | 0.50 | 0.59 | 560 | 195 | 733 | 3,837 | 19 |
| 2024-Q4* | 2025-03-05 | 3,599 | -37~EBIT | -148~ | -0.33*≈ | 0.16 | 388 | 172 | 461 | 3,735 | 129 |
| 2024-Q3* | 2024-11-06 | 3,832 | -107~EBIT | 227~ | 0.50*≈ | 0.58 | -8 | 357 | 460 | 3,758 | 15 |
| 2024-Q2* | 2024-08-01 | 3,930 | 180EBIT | 1 | 0.53*≈ | 0.50 | 578 | 217 | 521 | 4,169 | 13 |
| 2024-Q1* | 2024-05-08 | 3,796 | 252EBIT | 160~ | 0.33 | 0.42 | 522 | 127 | 794 | 3,855 | 10 |
| 2023-Q4* | 2024-03-04 | 3,604 | -33~EBIT | -144~ | -0.32*≈ | -0.12 | 1,663 | 515 | 749 | 3,906 | 119 |
| 2023-Q3* | 2023-11-07 | 3,771 | – | -91~ | -0.21 | 0.41 | 16 | 469 | 588 | 4,225 | 5 |
| 2023-Q2* | 2023-08-10 | 3,886 | -51EBIT | -266~ | -0.58≈ | 0.26 | 13 | -203 | 398 | 4,676 | 14 |
| 2023-Q1* | 2023-05-09 | 4,005~ | – | 49~ | 0.11*≈ | 0.25 | -36 | 21 | 634 | 3,824 | 1 |
* derived: values with formula provenance (hover); Q4 = FY − 9M · H2 = FY − H1 · EPS via implied shares · net debt = financial debt − cash · FCF = OCF − |capex|.
Columns not reported in this reporting cadence are hidden: Op. income (adj.) (not reported in any source for these periods).
Advertisement
Balance Sheet & Cash Flow (€m)#
Point-in-time balance sheet items (e.g. cash, financial debt) and cash flow items (operating cash flow, investments/capex) per fiscal year, half-year and quarter. All values are extracted automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original. Methodology
Fiscal years
Amounts in €m · as reported
| Period | Published | Cash | Debt | Net Debt | D&A | OCF | Capex | FCF | Source |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | 2026-03-04 | 495 | 4,165 | 3,670 | 1,203 | 1,443 | 748 | 695 | 25 |
| FY2024 | 2025-03-05 | 461 | 4,196 | 3,735 | 1,117 | 1,713 | 840 | 873 | 17 |
| FY2023 | 2024-02-26 | 749 | 4,655 | 3,906 | 1,841 | 1,594 | 793 | 801 | 9 |
Quarters
Amounts in €m · as reported
| Period | Published | Cash | Debt | Net Debt | D&A | OCF | Capex | FCF | Source |
|---|---|---|---|---|---|---|---|---|---|
| 2026-Q2 | 2026-08-04 | 390 | 4,465 | 4,075 | 376 | 229 | 180 | 49 | 137 |
| 2026-Q1 | 2026-05-07 | 589 | 4,155 | 3,566 | 239 | 407 | 224 | 183 | 27 |
| 2025-Q4 | 2026-03-04 | 495 | 4,165 | 3,670 | 275 | 612 | 201 | 411 | 25 |
| 2025-Q3 | 2025-11-03 | 454 | 4,493 | 4,039 | 428 | 481 | 181 | 300 | 30 |
| 2025-Q2 | 2025-08-01 | 379 | 4,801 | 4,422 | 260 | -35 | 176 | -211 | 21 |
| 2025-Q1 | 2025-05-09 | 733 | 4,570 | 3,837 | 240 | 385 | 190 | 195 | 19 |
| 2024-Q4 | 2025-03-05 | 461 | 4,196 | 3,735 | 368 | 438 | 266 | 172 | 129 |
| 2024-Q3 | 2024-11-06 | 460 | 4,218 | 3,758 | 234 | 537 | 180 | 357 | 15 |
| 2024-Q2 | 2024-08-01 | 521 | 4,690 | 4,169 | 250 | 360 | 143 | 217 | 13 |
| 2024-Q1 | 2024-05-08 | 794 | 4,649 | 3,855 | 265 | 378 | 251 | 127 | 10 |
| 2023-Q4 | 2024-03-04 | 749 | 4,655 | 3,906 | 281 | 703 | 188 | 515 | 119 |
| 2023-Q3 | 2023-11-07 | 588 | 4,813 | 4,225 | 574 | 631 | 162 | 469 | 5 |
| 2023-Q2 | 2023-08-10 | 398 | 5,074 | 4,676 | 675 | 34 | 237 | -203 | 14 |
| 2023-Q1 | 2023-05-09 | 634 | 4,458 | 3,824 | 311 | 227 | 206 | 21 | 1 |
Debt = long-term + current · Net debt = debt − cash · FCF = OCF − capex.
Advertisement
Revenue by Type (as of 2026-Q2 · EURm · 13/25)#
Revenue split by segment or product type, exactly as the company itself reports it. Methodology
| Segment | Since | Period | Basis | Revenue | Growth | Margin | Source |
|---|---|---|---|---|---|---|---|
| Infrastructure (incl. C4 business) / Other | 2025-Q1 | FY2026 | 12M? | 2,625 | – | 4% | 33 |
| Additives | 2026-Q1 | 2026-Q1 | 3M | 920 | – | 13.5% | 28 |
| Inorganics | 2026-Q1 | 2026-Q1 | 3M | 577 | – | – | 28 |
| Care | 2026-Q1 | 2026-Q1 | 3M | 414 | – | 17% | 28 |
| Organics | 2026-Q1 | 2026-Q1 | 3M | 390 | – | – | 28 |
| Infrastructure (SYNEQT + Oxeno businesses) / Other | 2025-Q1 | 2026-Q2 | 3M | 643 | – | – | 30 |
| Advanced Technologies | 2024-Q2 | FY2026 | 12M? | 6,145 | – | 17% | 33 |
| Custom Solutions | 2024-Q2 | FY2026 | 12M? | 5,531 | – | 17% | 33 |
| Infrastructure / Other | 2024-Q1 | 2026-Q2 | 3M | 824 | – | – | 31 |
| Smart Materials | 2022-Q2 | 2025-Q1 | 3M | 1,098 | 0% | 13.6% | 19 |
| Nutrition & Care | 2022-Q2 | 2025-Q1 | 3M | 1,007 | 12% | 19.6% | 19 |
| Specialty Additives | 2022-Q2 | 2025-Q1 | 3M | 923 | 1% | 21.8% | 19 |
| Animal Nutrition | 2022-Q2 | 2026-Q1 | 3M | 484 | – | – | 28 |
| Enabling functions, other activities, consolidation | FY2023 | FY2023 | 12M | 6,249 | – | – | 9 |
| Technology & Infrastructure | FY2023 | FY2023 | 12M | 1,073 | – | – | 9 |
| Enabling functions, other activities | FY2023 | FY2023 | 12M | 53 | – | – | 9 |
| Technology & Infrastructure and Others | FY2023 | FY2023 | 12M | -57 | – | – | 9 |
| Services, Corporate & Others | 2023-Q1 | 2023-Q1 | 3M | 303 | – | – | 2 |
| Technology & Infrastructure (T&I) / Other | FY2022 | 2024-Q1 | 3M | 249 | -18% | – | 12 |
| T&I / Other | 2022-Q2 | FY2024 | 12M | 3,365 | – | – | 17 |
| Smart Materials - Inorganics | 2022-Q2 | 2023-Q2 | 3M | 860 | -5% | – | 3 |
| Performance Materials | 2022-Q2 | 2024-Q3 | 3M | 557 | -10% | 3.4% | 16 |
| Health & Care | 2022-Q2 | 2023-Q2 | 3M | 445 | 3% | – | 3 |
| Smart Materials - Polymers | 2022-Q2 | 2023-Q2 | 3M | 328 | -9% | – | 3 |
| Technology & Infrastructure / Other | 2022-Q2 | 2024-Q2 | 3M | 286 | 4% | – | 13 |
Advertisement
Products & M&A (13/53 active+recent)#
Product announcements from the reports; market launches, approvals, partnerships; with first mention (date) and source. Methodology
| Product/Line | Since | Status | Source |
|---|---|---|---|
| PPA for offshore windpark with RWE (2×) | 2026 | Planned | 8 |
| Expansion of precipitated silica capacity in US | 2026 | Planned | 8 |
| PA12 capacity expansion in Germany | 2025-12 | Planned | 25 |
| Metal Oxides plant ramp-up in Japan | 2025-12 | Planned | 25 |
| Collaboration with hp Inc. on 3D printing PA12 for drone applications | 2025-12 | Planned | 25 |
| Biosurfactants plant completion | 2025-06 | Planned | 6 |
| Capital Markets Day | 2025-05 | Planned | 20 |
| PA12 plant ramp-up | 2025-03 | Planned | 20 |
| Biosurfactants plant utilization increase | 2025-03 | Planned | 20 |
| PPA for photovoltaic park with Vattenfall | 2025 | Planned | 8 |
| Lipid Innovation Center facility in Lafayette, Indiana | 2025 | Planned | 9 |
| Fumed aluminum oxide plant Japan (5×) | 2025 | Launched | 25 |
| Biosurfactants expansion in Slovakia (3×) | 2024 | Planned | 25 |
| Alkoxides plant Singapore (4×) | 2025-12 | Planned | 5 |
| SEPURAN® membranes capacity expansion (2×) | 2025 | Planned | 6 |
| US Animal Nutrition backward integration | 2024-12 | Planned | 4 |
| ROHACELL® performance foams in urban air mobility applications | 2024-12 | Launched | 17 |
| Low CO2 footprint viscosity modifiers for recycled polymer content | 2024-12 | Launched | 17 |
| High performance polymers for e-mobility solutions | 2024-12 | Launched | 17 |
| Circular silica from rice husk ash (ULTRASIL® eCO) with ISCC+ certification | 2024-12 | Launched | 17 |
| Biosurfactants from new production facility | 2024-12 | Launched | 17 |
| New Innovation Growth Areas - Advance Precision Biosolutions, Accelerate Energy Transition, Enable Circular Economy targeting €1.5 bn additional sales by 2032 | 2024-09 | Planned | 16 |
| Innovation Growth Areas | 2024-09 | Planned | 15 |
| First world-scale biosurfactants plant inauguration | 2024-05 | Launched | 14 |
| JV market entry for gut health products | 2024-03 | Planned | 6 |
| Ultra-high-purity colloidal silicon dioxide facility in Weston, Michigan | 2024 | Planned | 9 |
| Lipid production facility for mRNA-based therapies | 2024 | Planned | 8 |
| Singapore PA12 plant expansion | 2023-12 | Planned | 4 |
| Capacity adjustments in Specialty Additives | 2023-12 | Planned | 5 |
| Biosurfactants plant start-up (2×) | 2023-12 | Planned | 10 |
| PA12 plant maintenance shutdown | 2023-06 | Planned | 1 |
| New PA12 production facility ground-breaking and ramp-up | 2023-03 | Planned | 2 |
| Lipid production facility in US | 2023-03 | Planned | 2 |
| Treated municipal wastewater project in Antwerp for cooling and production use | 2023 | Planned | 9 |
| Rhamnolipid production facility in Slovenská Ľupča, Slovakia (2×) | 2023 | Launched | 9 |
| Pharmaceutical lipids production facility at Tippecanoe site in Lafayette, Indiana (USA) | 2023 | Planned | 9 |
| New alkoxides facility in Singapore for PET plastic chemical recycling | 2023 | Planned | 9 |
| Modernization of ROHACELL® production in Darmstadt, Germany (2×) | 2023 | Planned | 9 |
| Methionine production facility in Mobile, Alabama (USA) | 2023 | Planned | 9 |
| Joint venture with Wynca Group in China for new fumed silicas production facility in Zhenjiang, China | 2023 | Planned | 9 |
| Hollow fiber spinning facility in Schörfling | 2023 | Launched | 9 |
| Green hydrogen electrolyzer at Herne site | 2023 | Planned | 9 |
| Gas separation membranes production plant at Schörfling (Austria) | 2023 | Launched | 9 |
| Expansion of hollow fiber membrane production capacity at Schörfling, Austria | 2023 | Planned | 9 |
| ECOHANCE® product program | 2023 | Launched | 9 |
| ECOHANCE® Care PSC3 fatty acid skincare product from post-industrial plant-based residues | 2023 | Launched | 9 |
| Construction of new carbon-neutral alkoxides facility in Singapore | 2023 | Planned | 9 |
| Construction and operation of the gas and steam turbine power plant (power plant VII) in Marl, Germany | 2023 | Planned | 9 |
| Construction and operation of the Lipid Innovation Center in Tippecanoe, Indiana, USA | 2023 | Planned | 9 |
| Construction and operation of a production facility for methionine on Jurong Island, Singapore | 2023 | Planned | 9 |
| Construction and operation of a new polyamide 12 production line in Marl, Germany | 2023 | Planned | 9 |
| Alkoxides production facility in Southeast Asia (Singapore site Jurong Island) | 2023 | Planned | 9 |
Advertisement
M&A (37)#
All recorded acquisitions (purchases) and divestitures/exits with date, short description and source; deliberately including smaller transactions that summaries often miss. Methodology
Acquisitions · 14Divestitures/exits · 22older: 1 (in the table)
Acquisitions
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| Oxeno backward integration in Mobile | 2026-06 | Completed | 31 |
| He Dreiht offshore wind farm power purchase agreement (3×) | 2026 | Announced | 9 |
| Additional power purchase agreements with Vattenfall and RWE for renewable electricity | 2026 | Announced | 9 |
| Infrastructure carve-out SYNEQT (2×) | 2025-12 | Completed | 24 |
| Senior bond repayment | 2025-09 | Completed | 24 |
| Green hybrid bond issuance | 2025-09 | Completed | 24 |
| Vattenfall photovoltaic locations power purchase agreement | 2025 | Announced | 9 |
| Health Care business line realignment - transition to system solutions and core growth areas | 2024 | Completed | 16 |
| Coating & Adhesive Resins business line realignment | 2024 | Completed | 16 |
| Alkoxides business integration into Smart Materials catalyst business | 2023-01 | Completed | 2 |
| Acquisition of the Porocel Group, Houston, Texas, USA | 2023 | Completed | 9 |
| Acquisition of Thai Peroxide Company Ltd., Bangkok (Thailand) (2×) | 2023 | Completed | 9 |
| Acquisition of Novachem S.R.L. (Argentinean cosmetic active ingredient company), Buenos Aires | 2023 | Completed | 9 |
| Acquisition of Infinitec Activos SL, Barcelona, Spain | 2023 | Completed | 9 |
Divestitures / exits
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| Witten site closure | 2026-06 | Divested | 31 |
| Polyolefins transfer to C site | 2026-06 | Divested | 31 |
| Hanau closure | 2026-06 | Divested | 31 |
| Health Care production discontinuation in Hanau | 2025 | Divested | 16 |
| Carve-out of Marl & Wesseling sites | 2025 | Divested | 17 |
| Shut-down of production plant in Hanau (Germany) | 2024-12 | Divested | 17 |
| Evaluation of strategic options for Marl & Wesseling sites | 2024-12 | Divested | 17 |
| Superabsorbers business divestiture | 2024-09 | Divested | 14 |
| Superabsorber business sale | 2024-08 | Divested | 15 |
| Sale of superabsorbers business | 2024-08 | Divested | 16 |
| Superabsorbers divestment | 2024-06 | Divested | 10 |
| Superabsorbents business | 2024 | Divested | 9 |
| Divestment of Superabsorber business | 2024 | Divested | 17 |
| Methionine plant shutdown in Singapore | 2023-12 | Divested | 7 |
| Sale of Superabsorbents business | 2023-06 | Divested | 9 |
| Sale of Lulsdorf site (3x) | 2023-06 | Divested | 1 |
| Lulsdorf site and functional solutions business | 2023-06 | Divested | 9 |
| Lulsdorf site divestment including potash derivatives and cyanuric chlorides production | 2023-04 | Divested | 2 |
| Superabsorber divestment | 2023 | Divested | 8 |
| Performance Intermediates business | 2023 | Divested | 9 |
| Lülsdorf site (Germany) and related cyanuric chloride business | 2023 | Divested | 9 |
| C4 chemicals business | 2023 | Divested | 9 |
| TAA derivatives business of Specialty Additives division | 2022 | Divested | 9 |
Advertisement
Risks (144 since the annual report of 2024-02-26, 151 tracked in total)#
Risk factors the company itself names in its reports, merged by topic across periods, with category, first and last mention and source. Methodology
| Risk | Category | First reported | Last reported |
|---|---|---|---|
| Weak demand and structural headwinds noted as ongoing market challenges | Macro | 2026-Q2 2026-08-04 31 | 2026-Q2 2026-08-04 31 |
| Additives business partly supported by war-related supply chain disruptions affecting customer availability | Customers | FY2023 2024-02-26 9 | 2026-Q2 2026-08-04 31 |
| Middle East geopolitical situation benefiting margins in Oxeno C4 business through higher pricing | Supply chain | 2024-Q1 2024-06-25 2 | 2026-Q2 2026-08-04 31 |
| EUR/USD sensitivity of +/-€5 m adj. EBITDA per cent impacts financial results | Financial | 2023-Q4 2024-03-04 7 | 2026-Q2 2026-08-04 31 |
| Total leverage at 2.4x in H1 2026, requiring management to deliver on cash conversion targets | Financial | 2023-Q1 2023-05-09 1 | 2026-Q2 2026-08-04 31 |
| Force Majeure on methionine supply in Singapore with higher variable costs and raw material shortages affecting Animal Nutrition segment | Supply chain | 2026-Q1 2026-05-08 28 | 2026-Q1 2026-05-08 28 |
| Raw material shortages in Singapore and rising raw material costs (Animal Nutrition segment) | Supply chain | 2026-Q1 2026-05-08 26 | 2026-Q1 2026-05-08 26 |
| Fixed cost increases difficult to compensate in downturn; ~€5 bn fixed costs with ~4% general increase | Financial | 2025-Q4 2026-03-04 25 | 2025-Q4 2026-03-04 25 |
| Oxeno C4 business impaired at €170 m in Q3 2025 reflecting weak market conditions | Legal | 2025-Q4 2026-03-04 25 | 2025-Q4 2026-03-04 25 |
| Elevated net working capital at 19.3% of sales above long-term average of 16% | Financial | 2025-Q2 2025-08-01 22 | 2025-Q2 2025-08-01 22 |
| Weak demand in Oxeno C4 business significantly reducing segment earnings | Customers | 2025-Q2 2025-08-01 22 | 2025-Q2 2025-08-01 22 |
| Continued high competitive intensity in Crosslinkers with margin pressure mainly in EMEA and Asia | Competition | 2025-Q2 2025-08-01 22 | 2025-Q2 2025-08-01 22 |
| Performance Intermediates (C4) business with weak start in FY 2025; intended divestment remains unchanged | strategie | 2024-Q4 2025-03-05 17 | 2024-Q4 2025-03-05 17 |
| Performance Materials Superabsorbers business included until closing expected in Q3 2024 | Legal | 2024-Q2 2024-08-01 14 | 2024-Q2 2024-08-01 14 |
| Customer destocking across all segments putting pressure on volumes and prices | Financial | 2023-Q4 2024-03-04 7 | 2024-Q1 2024-06-25 4 |
| Elevated raw material costs combined with falling product prices in Methionine and other segments | Financial | 2023-Q4 2024-03-04 8 | 2024-Q1 2024-06-25 4 |
| Intense price pressure in Animal Nutrition, C4 chain and Specialties segments | Market | 2023-Q2 2023-08-10 3 | 2024-Q1 2024-06-25 4 |
| Impairment of €233 m in context of planned divestments, particularly Superabsorber business | Legal | 2024-Q1 2024-06-25 6 | 2024-Q1 2024-06-25 6 |
| Multiple planned production shutdowns affecting PA12 plants and HPPO capacity in Asia | Technology | 2024-Q1 2024-06-25 4 | 2024-Q1 2024-06-25 4 |
| Objective for women to account for 30 percent of executives at top two management levels by 2026 | ESG | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Contingent liabilities EUR 64 million; EUR 29 million from venture capital fund obligations | Financial | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Restructuring provisions reflect costs for workforce optimization affecting sales and administrative functions | Financial | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Expected credit loss assessment per IFRS 9 impairment model | Financial | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Goodwill EUR 4.581 billion tested for impairment; no impairment identified | Financial | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| € 736 million impairment losses recognized primarily on Superabsorbents and methionine facilities | Financial | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Impairment losses of €435 million related to methionine facilities and production facilities indicate asset value risks | Financial | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Integrated production facilities for fumed silicas fully impaired; coatings and adhesives production network written down to almost zero | Financial | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Defined benefit obligations increased from €8,344 million in 2022 to €9,004 million in 2023 due to lower discount rates | Financial | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Property plant equipment EUR 6.294 billion; EUR 452 million impairment recognized | Financial | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Food quality and food safety concerns represent potential risk factor for amino acids business especially in Asia | Customers | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Significant customer destocking across industrial sectors exacerbated weak demand conditions | Customers | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Single sourcing and restricted short-term availability risks for Nutrition Care and Specialty Additives divisions | Supply chain | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Validation process for major raw material suppliers at 67% completion; ongoing work to achieve full supplier sustainability assessment by 2025 | Supply chain | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Early employee turnover at 2.2 percent; goal is further reduction in early turnover rate | People | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Intensifying shortage of skilled workers requires increased retention, development, and recruitment activities | People | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Environmental protection provisions of €269 million are required for recultivation and site decontamination obligations | Legal | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Carbon Border Adjustment Mechanism certificate requirements from 2026 for imported goods including aluminum ammonia iron electricity steel hydrogen cement | Regulatory | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Provisions include €72 million for the obligation to surrender emission allowances under European emissions trading | Regulatory | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Fourth EU ETS trading period structure with more stringent free CO2 allowance benchmark creates cost risks for Evonik facilities | Regulatory | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Sale of Superabsorber signed; Performance Materials divestment ongoing with continued low demand only modest recovery expected | strategie | 2023-Q4 2024-03-04 8 | 2023-Q4 2024-03-04 8 |
| Underutilization of production facilities due to weak demand impacted operational efficiency | Technology | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Significant price declines in Animal Nutrition and Performance Intermediates businesses | Competition | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| EUR/USD sensitivity of +/- 1 USD cent equals approximately +/- €5 million on adjusted EBITDA on full-year basis | Financial | 2026-Q1 2026-05-08 28 | 2026-Q1 2026-05-08 28 |
| Net financial debt leverage stable at 1.6x with pension provisions at €1,547 million; limited headroom for further debt increases | Financial | 2026-Q1 2026-05-08 28 | 2026-Q1 2026-05-08 28 |
| War in Middle East causing supply chain disruptions and input cost inflation, with risks concentrated in H2 2026 | Geopolitics | 2026-Q1 2026-05-08 26 | 2026-Q1 2026-05-08 28 |
| Risk of inflation-led demand slowdown and volume destocking potential in H2 2026, especially if raw material and energy costs continue rising | Macro | 2026-Q1 2026-05-08 28 | 2026-Q1 2026-05-08 28 |
| Risk of inflation-led demand slowdown in H2 2026 | Macro | 2026-Q1 2026-05-08 26 | 2026-Q1 2026-05-08 26 |
| Persistent weak demand environment continuing from H2 2025 into Q1 2026 across most segments, with limited visible improvement in January-February | Market | 2023-Q2 2023-08-10 3 | 2026-Q1 2026-05-08 28 |
| Potential destocking in second half of 2026 | Market | 2026-Q1 2026-05-08 26 | 2026-Q1 2026-05-08 26 |
| Weak demand environment persisting from H2 2025 into Q1 2026 | Market | 2023-Q3 2023-11-07 5 | 2026-Q1 2026-05-08 26 |
| Likely continued FX headwind from USD weakness | Financial | 2025-Q3 2025-11-04 24 | 2025-Q4 2026-03-04 25 |
| Protectionist pressures | Macro | 2025-Q4 2026-03-04 25 | 2025-Q4 2026-03-04 25 |
| No pronounced demand recovery expected in key end markets | Market | 2023-Q4 2024-03-04 8 | 2025-Q4 2026-03-04 25 |
| Global industrial production expected to stay below 2025 level at ~1.7% growth | Market | 2025-Q4 2026-03-04 25 | 2025-Q4 2026-03-04 25 |
| Increasing regulation affecting operations | Regulatory | 2025-Q4 2026-03-04 25 | 2025-Q4 2026-03-04 25 |
| Continued Chinese competition in selected products | Competition | 2025-Q4 2026-03-04 25 | 2025-Q4 2026-03-04 25 |
| Methionine capacity additions by competitors likely resulting in price normalization | Competition | 2025-Q4 2026-03-04 25 | 2025-Q4 2026-03-04 25 |
| Customers acting cautiously across all segments and end markets | Customers | 2025-Q3 2025-11-04 24 | 2025-Q3 2025-11-04 24 |
| Weak demand environment across nearly all end markets affecting pricing and volume ability | Macro | 2025-Q3 2025-11-03 23 | 2025-Q3 2025-11-03 23 |
| Weak industrial GDP growth impacting demand | Macro | 2025-Q3 2025-11-04 24 | 2025-Q3 2025-11-04 24 |
| Long-dated pension obligations with approximately 13 years duration | Legal | FY2023 2024-02-26 9 | 2025-Q3 2025-11-04 24 |
| Continued high competitive intensity in Crosslinkers segment | Competition | 2025-Q3 2025-11-04 24 | 2025-Q3 2025-11-04 24 |
| Strong USD headwind negatively impacting financial results and EBITDA | Financial | 2025-Q2 2025-08-01 22 | 2025-Q2 2025-08-01 22 |
| Tougher global macro environment with low consumer confidence and customer cautiousness affecting demand | Macro | 2025-Q2 2025-08-01 21 | 2025-Q2 2025-08-01 22 |
| Weakening customer & end consumer demand, very low visibility | Macro | 2023-Q2 2023-08-10 3 | 2025-Q1 2025-05-12 20 |
| Lower global growth or recession risk | Macro | 2025-Q1 2025-05-12 20 | 2025-Q1 2025-05-12 20 |
| Higher inflation and lower growth in the US | Macro | 2025-Q1 2025-05-12 20 | 2025-Q1 2025-05-12 20 |
| Tariffs & disruptions in specific supply chains | Market | 2025-Q1 2025-05-12 20 | 2025-Q1 2025-05-12 20 |
| Further escalating trade and tariff tensions | Market | 2025-Q1 2025-05-12 20 | 2025-Q1 2025-05-12 20 |
| Increasing competition outside US | Competition | 2025-Q1 2025-05-12 20 | 2025-Q1 2025-05-12 20 |
| High energy costs in Europe; mitigation through increased green electricity share and hedging policy | Supply chain | 2023-Q2 2023-08-10 3 | 2024-Q4 2025-03-05 17 |
| Low GDP growth and weak end markets requiring positioned portfolio in attractive niches | Macro | 2024-Q4 2025-03-05 17 | 2024-Q4 2025-03-05 17 |
| Germany weakness with European energy cost challenges and rising protectionism in Europe, US, China | Macro | 2024-Q4 2025-03-05 17 | 2024-Q4 2025-03-05 17 |
| Evaluation of strategic options for major sites; potential divestments and partnership models under consideration | Legal | 2024-Q4 2025-03-05 17 | 2024-Q4 2025-03-05 17 |
| Weak end market demand in rubber, tires and automotive persisting | Customers | 2024-Q1 2024-05-08 10 | 2024-Q3 2024-11-06 15 |
| Weak end market demand in rubber, tires and automotive persisting in butadiene | Macro | 2024-Q3 2024-11-06 16 | 2024-Q3 2024-11-06 16 |
| EUR/USD sensitivity of +/-€10 m adj. EBITDA per cent | Macro | 2024-Q3 2024-11-06 15 | 2024-Q3 2024-11-06 15 |
| Demand for hydrogen peroxide remains subdued in Asia | Macro | 2024-Q3 2024-11-06 16 | 2024-Q3 2024-11-06 16 |
| Strategic portfolio adjustments under constant review on Business Line level | Legal | 2024-Q3 2024-11-06 16 | 2024-Q3 2024-11-06 16 |
| Crosslinkers in continued tough competitive environment | Competition | 2024-Q3 2024-11-06 15 | 2024-Q3 2024-11-06 16 |
| Temporary global supply chain disruptions in oxo-alcohol and plasticizers benefited Q2; market normalized in June | Supply chain | 2024-Q2 2024-08-01 14 | 2024-Q2 2024-08-01 14 |
| Challenging macro environment persists; no broad-based macro improvement yet observed | Macro | 2023-Q4 2024-03-04 7 | 2024-Q2 2024-08-01 14 |
| Net financial debt leverage at 2.0x in Q3 2023, elevated compared to FY 2022 level of 1.2x | Financial | 2024-Q1 2024-06-25 6 | 2024-Q1 2024-06-25 6 |
| Geopolitical uncertainty in Europe remains; difficult macroeconomic environment for Chemicals | Geopolitics | 2024-Q1 2024-06-25 4 | 2024-Q1 2024-06-25 4 |
| Animal protein markets struggling with high feed costs and low margins; volumes lower than expected especially in China and Brazil | Customers | 2024-Q1 2024-06-25 2 | 2024-Q1 2024-06-25 2 |
| Destocking by customers in Specialty Additives; Asian exports competing in European and US markets | Supply chain | FY2023 2024-02-26 9 | 2024-Q1 2024-06-25 6 |
| EUR/USD sensitivity of +/-1 USD cent impacts adj. EBITDA by approximately €6 m on FY basis | Macro | FY2023 2024-02-26 9 | 2024-Q1 2024-06-25 6 |
| Geo-political uncertainties expected to persist throughout 2024 | Macro | 2024-Q1 2024-05-08 10 | 2024-Q1 2024-05-08 10 |
| High inflation and elevated interest rates impacting core geographic markets | Macro | 2024-Q1 2024-06-25 4 | 2024-Q1 2024-06-25 4 |
| Global GDP growth expected below 2023 level | Macro | 2024-Q1 2024-05-08 10 | 2024-Q1 2024-05-08 10 |
| Pricing pressures and pass-through of lower raw material costs affecting margins | Market | 2024-Q1 2024-06-25 6 | 2024-Q1 2024-06-25 6 |
| Price pressure in Animal Nutrition and C4 business; price declines faster than decreasing raw material prices | Market | 2023-Q3 2023-11-07 5 | 2024-Q1 2024-06-25 2 |
| Business portfolio focused on mission-critical solutions geared towards sustainability including energy transition and efficiency improvements | Regulatory | 2024-Q1 2024-06-25 2 | 2024-Q1 2024-06-25 2 |
| Challenging competitive environment in Crosslinkers business | Competition | 2023-Q4 2024-03-04 7 | 2024-Q1 2024-05-08 10 |
| Threat of cyberattacks classified as material risk with expected value over €100 million | Cyber | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Climate change effects including water stress and acute weather events such as low Rhine water levels affecting operations | ESG | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Stricter environmental regulations and potential amendments to European chemicals strategy creating compliance risks | ESG | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Rising carbon pricing in EU ETS and other regions affects investment decisions; internal carbon price forecast € 142/ton CO2 by 2030 | Financial | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Commodity price risks from procurement of raw materials and energy | Financial | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Credit risk of financial counterparties managed through investment-grade requirements | Financial | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Negative currency effects impacted group sales; Argentine peso depreciation in December 2023 led to substantial depreciation effects on foreign currency liabilities. | Financial | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Restrictive monetary policy deteriorated financing conditions for companies and households | Financial | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Exchange rate exposure in USD and CNY/CNH from operations and financing | Financial | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Exposure to interest rate changes on variable-rate financial instruments | Financial | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Material lease liabilities and ongoing cash outflows for lease obligations | Financial | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Liquidity management through cash pools and committed credit facilities | Financial | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Market opportunities and risks from management of pension plan assets requiring active risk management and detailed risk controlling | Financial | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| 19 sites classified as high water risk by 2030; 26 sites high or very high risk by 2050 based on WWF Water Risk Filter analysis | Financial | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Animal Nutrition subject to commodity price volatility with methionine pricing showing first qoq increase after five quarters | Customers | 2023-Q4 2024-03-04 7 | 2023-Q4 2024-03-04 7 |
| High capital goods prices and service cost increases due to skilled worker shortages | Supply chain | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Limited short-term availability of low-carbon raw materials drives need for alternative sourcing strategies and supplier engagement | Supply chain | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| High volatility in availability and prices of strategic raw materials especially petrochemical feedstocks | Supply chain | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Short and mid-term bottlenecks in availability of precursors intermediates and renewable raw materials | Supply chain | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Ongoing construction sector crisis high debt levels and weak export demand could hamper Chinese economic growth | Macro | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Longest demand slowdown in recent history with seven quarters without notable pickup; volumes in kt remain lower | Macro | 2023-Q4 2024-03-04 8 | 2023-Q4 2024-03-04 8 |
| Ongoing geopolitical conflicts including Ukraine war and Middle East conflict affecting global economy and energy markets | Macro | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Geopolitical situation required extending coal-fired power plant operation in Marl beyond planned 2022 decommissioning date | Macro | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Restrictive monetary policy by central banks dampening investment and consumption with risk of renewed inflation through second-round effects | Macro | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Raw material basket expected to move sideways with energy costs only slightly lower due to long-term hedging | Macro | 2023-Q1 2023-05-09 1 | 2023-Q4 2024-03-04 7 |
| Reduction in price and volume of C4 chemicals material risk with expected value over €100 million | Market | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Slower-than-expected economic recovery in China following end of zero-Covid policy | Market | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| High energy prices particularly impacting energy-intensive chemical production in Europe | Market | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Changes in exchange rates material risk; US dollar and Chinese renminbi yuan most relevant | Market | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Geopolitical tensions including Russia-Ukraine conflict and Middle East unrest create persistent business uncertainty | Market | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Weak global economic growth and recession dampened demand across specialty chemicals businesses | Market | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Persistent global inflation elevated costs despite some moderation during 2023 | Market | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Rising inflation could increase future salary and pension increases in defined benefit plans | Market | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Pandemic could cause unforeseen staff shortages through sickness quarantine care responsibilities and civic obligations | People | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Possible loss of key personnel and difficulties in attracting and hiring skilled and talented staff in tight labor market | People | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Subject to multiple emissions trading systems across geographies; compliance costs and regulatory obligations vary by region | Legal | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Breaches of applicable data protection laws could result in fines reputational damage and individual compensation claims | Legal | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| EU emissions trading system and Corporate Sustainability Due Diligence Directive impose regulatory requirements | Legal | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Disposal of assets resulted in losses of € 47 million; sale of TAA derivatives business and Lülsdorf site generated losses | Legal | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Exposed to liability risks especially in connection with product liability patent law tax law and environmental law | Legal | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Possible amendment of European emissions trading regulations and changes to energy fees and levies | Regulatory | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| EU taxonomy currently focuses on commodity chemicals with limited coverage of specialty chemicals; only 17% of turnover taxonomy-eligible | Regulatory | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| National emissions trading system heating and transportation sectors affecting German sites since 2021 | Regulatory | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Portfolio transformation and compliance with new sustainability reporting directives (CSRD) require substantial implementation efforts through fiscal 2024. | Regulatory | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Extraordinarily high tax rate of 48% for FY 2023 due to exceptional items; expected to return to ~30% in 2024 | Regulatory | 2023-Q4 2024-03-04 8 | 2023-Q4 2024-03-04 8 |
| OECD Pillar Two global minimum tax of 15% came into force Dec 28 2023; estimated impact 1% on effective tax rate from 2024 | Regulatory | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Capital expenditure projects require substantial long-term investment; expansion of production facilities for next-generation solutions ongoing with extended timelines. | strategie | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Risks from digitalization artificial intelligence Internet of Things including inadequate technical equipment inadequate cybersecurity robustness | Technology | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| Scheduled maintenance shutdowns at production plants, particularly for high-performance polymer polyamide 12, weighed on earnings in 2023. | Technology | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
| 37% of production sites located within one kilometer of conservation or key biodiversity areas; declining biodiversity affects business operations | Environment | FY2023 2024-02-26 9 | FY2023 2024-02-26 9 |
Advertisement
Reported KPIs (as disclosed) (266)#
Figures the company discloses itself in addition to the standard financials; order intake, recurring revenue, user or unit counts, adjusted measures. Methodology
Company-specific KPIs verbatim from the filings (English, as disclosed; not normalised). Balance-sheet and boilerplate items filtered.
| Date | Period | KPI | Value / change | Source |
|---|---|---|---|---|
| 2026-08-04 | 2026-Q2 | Total Leverage H1 2026 | 2.4x | 31 |
| 2026-08-04 | 2026-Q2 | Total Leverage 2025 | 2.3x | 31 |
| 2026-08-04 | 2026-Q2 | Total Leverage 2024 | 3.0x | 31 |
| 2026-08-04 | 2026-Q2 | Sales share with Next Generation Solutions | 48% | 30 |
| 2026-08-04 | 2026-Q2 | ROCE | 6.1% | 30 |
| 2026-08-04 | 2026-Q2 | R&D expenses | 418 € million | 30 |
| 2026-08-04 | 2026-Q2 | Production output | 6.0 million metric tons | 30 |
| 2026-08-04 | 2026-Q2 | Procurement volume | 9.8 € billion | 30 |
| 2026-08-04 | 2026-Q2 | Pension funding ratio | ~85% | 31 |
| 2026-08-04 | 2026-Q2 | Net financial debt leverage | 1.8x | 31 |
| 2026-08-04 | 2026-Q2 | Leverage | 2.6x | 29 |
| 2026-08-04 | 2026-Q2 | Financial debt leverage | 1.8x | 29 |
| 2026-08-04 | 2026-Q2 | Employees (continuing operations) | 30,356 | 30 |
| 2026-08-04 | 2026-Q2 | EUR USD sensitivity adj EBITDA | +/-1 USD cent = -/+ ~€5 m | 31 |
| 2026-08-04 | 2026-Q2 | Dividend | 1.00 € | 30 |
| 2026-08-04 | 2026-Q2 | Cash Conversion Rate 2026E | ~40% | 31 |
| 2026-08-04 | 2026-Q2 | Cash Conversion Rate 2025 | 37% | 31 |
| 2026-08-04 | 2026-Q2 | Cash Conversion Rate | 37% | 30 |
| 2026-08-04 | 2026-Q2 | Adj. EBITDA margin Q2 2026 | 16.2% | 31 |
| 2026-08-04 | 2026-Q2 | Adj. EBITDA margin Q2 2025 | 14.5% | 31 |
| 2026-08-04 | 2026-Q2 | Adj. EBITDA margin Q1 2026 | 13.9% | 31 |
| 2026-07-15 | 2026-Q2 | ROCE FY2026E | 7.8 | 33 |
| 2026-07-15 | 2026-Q2 | ROCE | 6.1 | 33 |
| 2026-05-08 | 2026-Q1 | Pension funding ratio | ~85% | 28 |
| 2026-05-08 | 2026-Q1 | Leverage | 2.5x | 26 |
| 2026-05-08 | 2026-Q1 | Leverage | 1.6x | 28 |
| 2026-05-08 | 2026-Q1 | Financial debt leverage | 1.6x | 26 |
| 2026-05-08 | 2026-Q1 | Cash Conversion Rate | ~40% | 28 |
| 2026-05-07 | 2026-Q1 | Sales share with Next Generation Solutions | 48% | 27 |
| 2026-05-07 | 2026-Q1 | ROCE | 6.1% | 27 |
| 2026-05-07 | 2026-Q1 | Dividend | 1.00 € | 27 |
| 2026-03-23 | 2025-Q4 | ROCE FY2026E | 6.0 | 32 |
| 2026-03-23 | 2025-Q4 | ROCE | 6.1 | 32 |
| 2026-03-04 | 2025-Q4 | ROCE | 6.1 | 25 |
| 2026-03-04 | 2025-Q4 | Net Financial Debt Leverage | 1.6x | 25 |
| 2026-03-04 | 2025-Q4 | NWC to Sales Ratio | 17.2% | 25 |
| 2026-03-04 | 2025-Q4 | Cash Conversion Rate | 37% | 25 |
| 2025-11-04 | 2025-Q3 | Net Working Capital to Sales | 19.5% | 24 |
| 2025-11-04 | 2025-Q3 | Net Financial Debt | 3,677 (EUR in € m) | 24 |
| 2025-11-04 | 2025-Q3 | Leverage | 1.8x | 24 |
| 2025-11-04 | 2025-Q3 | Adj. EBITDA Margin Q3 2025 | 13.2% | 24 |
| 2025-11-04 | 2025-Q3 | Adj. EBITDA Margin Q3 2024 | 15.1% | 24 |
| 2025-11-04 | 2025-Q3 | Adj. EBITDA Margin Q2 2025 | 14.5% | 24 |
| 2025-11-04 | 2025-Q3 | Adj. EBITDA LTM | 1,905 (EUR in € m) | 24 |
| 2025-11-03 | 2025-Q3 | Leverage | 2.5x | 23 |
| 2025-11-03 | 2025-Q3 | Financial Debt Leverage | 1.8x | 23 |
| 2025-08-01 | 2025-Q2 | ROCE | around prior-year level | 21 |
| 2025-08-01 | 2025-Q2 | NWC to Sales Ratio | 19.3% | 21 |
| 2025-08-01 | 2025-Q2 | Net Working Capital Ratio | 19.3 | 22 |
| 2025-08-01 | 2025-Q2 | net financial debt leverage | 1.8x | 22 |
| 2025-08-01 | 2025-Q2 | Net Financial Debt | 3,864 (EUR in € m) | 22 |
| 2025-08-01 | 2025-Q2 | Leverage | 2.5x | 21 |
| 2025-08-01 | 2025-Q2 | cash conversion rate | ~40% | 22 |
| 2025-08-01 | 2025-Q2 | adj. EBITDA margin | 14.5% | 21 |
| 2025-08-01 | 2025-Q2 | ROCE | around prior-year level | 22 |
| 2025-05-12 | 2025-Q1 | ROCE | above level of 2024 | 20 |
| 2025-05-12 | 2025-Q1 | Leverage | 2.0x | 18 |
| 2025-05-12 | 2025-Q1 | Free Cash Flow conversion rate | ~40% | 20 |
| 2025-05-12 | 2025-Q1 | discount rate | 4.0% | 18 |
| 2025-05-12 | 2025-Q1 | adjusted net debt | 4,258 (EUR in € m) | 20 |
| 2025-05-12 | 2025-Q1 | adj. tax rate | around long-term sustainable level of ~30% | 20 |
| 2025-05-12 | 2025-Q1 | adj. net financial result | around prior-year level | 20 |
| 2025-05-12 | 2025-Q1 | Adj. D&A | around prior-year level | 20 |
| 2025-05-09 | 2025-Q1 | women in management (circles 1-3) | 30.7% | 19 |
| 2025-05-09 | 2025-Q1 | women in management (circle 3) | 31.4% | 19 |
| 2025-05-09 | 2025-Q1 | women in senior management (circle 2) | 19.1% | 19 |
| 2025-05-09 | 2025-Q1 | women at executive level (circle 1) | 21.8% | 19 |
| 2025-05-09 | 2025-Q1 | use of renewable raw materials in production | 9.0% | 19 |
| 2025-05-09 | 2025-Q1 | total water intake | 431 (in million m³) | 19 |
| 2025-05-09 | 2025-Q1 | specific water intake | 32.2 | 19 |
| 2025-05-09 | 2025-Q1 | Scope 3 greenhouse gas emissions | 21.6 (million metric tons CO2) | 19 |
| 2025-05-09 | 2025-Q1 | Scope 2 greenhouse gas emissions | 1,670 (thousands metric tons CO2) | 19 |
| 2025-05-09 | 2025-Q1 | Scope 1 greenhouse gas emissions | 3,390 (thousands metric tons CO2) | 19 |
| 2025-05-09 | 2025-Q1 | Sales share with Next Generation Solutions | 45% | 19 |
| 2025-05-09 | 2025-Q1 | ROCE | 7.1% | 19 |
| 2025-05-09 | 2025-Q1 | R&D expenses | 459 (EUR € million) | 19 |
| 2025-05-09 | 2025-Q1 | production waste | 306 (thousand metric tons) | 19 |
| 2025-05-09 | 2025-Q1 | Production output | 7.3 (million metric tons) | 19 |
| 2025-05-09 | 2025-Q1 | Procurement volume | 10.5 (in € billion) | 19 |
| 2025-05-09 | 2025-Q1 | Occupational health performance index | 5.5 | 19 |
| 2025-05-09 | 2025-Q1 | Incident frequency rate | 0.44 | 19 |
| 2025-05-09 | 2025-Q1 | Employees (continuing operations) | 31,585 | 19 |
| 2025-05-09 | 2025-Q1 | Dividend | 1.17 | 19 |
| 2025-05-09 | 2025-Q1 | Cash Conversion Rate | 42% | 19 |
| 2025-05-09 | 2025-Q1 | Accident frequency rate | 0.14 | 19 |
| 2025-03-05 | 2024-Q4 | Total dividend payout | 545 | 17 |
| 2025-03-05 | 2024-Q4 | ROCE | 7.1% | 17 |
| 2025-03-05 | 2024-Q4 | Next Generation Solutions share | 45% | 17 |
| 2025-03-05 | 2024-Q4 | Net debt leverage | 1.5x | 17 |
| 2025-03-05 | 2024-Q4 | GHG emissions reduction | -20% | 17 |
| 2025-03-05 | 2024-Q4 | Dividend yield | ~6% | 17 |
| 2025-03-05 | 2024-Q4 | Dividend per share | 1.17 | 17 |
| 2025-03-05 | 2024-Q4 | Cash Conversion Rate | 42% | 17 |
| 2024-11-06 | 2024-Q3 | cash conversion rate | ~40% | 15 |
| 2024-11-06 | 2024-Q3 | Specialty Additives margin (Q3 2023) | 19.6% | 16 |
| 2024-11-06 | 2024-Q3 | Specialty Additives margin | 23.2% | 16 |
| 2024-11-06 | 2024-Q3 | Smart Materials margin (Q3 2023) | 12.3% | 16 |
| 2024-11-06 | 2024-Q3 | Smart Materials margin | 14.9% | 16 |
| 2024-11-06 | 2024-Q3 | ROCE | significantly above 3.4% | 15 |
| 2024-11-06 | 2024-Q3 | Performance Materials margin (Q3 2023) | 7.2% | 16 |
| 2024-11-06 | 2024-Q3 | Performance Materials margin | 3.4% | 16 |
| 2024-11-06 | 2024-Q3 | Nutrition & Care margin (Q3 2023) | 13.7% | 16 |
| 2024-11-06 | 2024-Q3 | Nutrition & Care margin | 19.5% | 16 |
| 2024-11-06 | 2024-Q3 | Net financial debt | 3,286 (EUR in € m) | 16 |
| 2024-11-06 | 2024-Q3 | Leverage (net debt/adj. EBITDA LTM) | 2.3x | 16 |
| 2024-11-06 | 2024-Q3 | Innovation Growth Areas sales target | €1.5 bn | 15 |
| 2024-11-06 | 2024-Q3 | Adj. EBITDA margin (Q3 2023) | 12.9% | 16 |
| 2024-11-06 | 2024-Q3 | Adj. EBITDA margin (Q2 2024) | 14.7% | 16 |
| 2024-11-06 | 2024-Q3 | Adj. EBITDA margin | 15.1% | 16 |
| 2024-11-06 | 2024-Q3 | 9M FCF | €701 m | 15 |
| 2024-08-01 | 2024-Q2 | Specialty Additives margin (Q2 2024) | 23.3% | 14 |
| 2024-08-01 | 2024-Q2 | Specialty Additives margin (Q2 2023) | 22.0% | 14 |
| 2024-08-01 | 2024-Q2 | Specialty Additives margin (Q1 2024) | 20.4% | 14 |
| 2024-08-01 | 2024-Q2 | Smart Materials margin (Q2 2024) | 14.9% | 14 |
| 2024-08-01 | 2024-Q2 | Smart Materials margin (Q2 2023) | 10.9% | 14 |
| 2024-08-01 | 2024-Q2 | Smart Materials margin (Q1 2024) | 14.5% | 14 |
| 2024-08-01 | 2024-Q2 | Q2 FCF | €217 m | 13 |
| 2024-08-01 | 2024-Q2 | Performance Materials margin (Q2 2024) | 8.0% | 14 |
| 2024-08-01 | 2024-Q2 | Performance Materials margin (Q2 2023) | 6.5% | 14 |
| 2024-08-01 | 2024-Q2 | Performance Materials margin (Q1 2024) | 6.7% | 14 |
| 2024-08-01 | 2024-Q2 | Nutrition & Care margin (Q2 2024) | 15.5% | 14 |
| 2024-08-01 | 2024-Q2 | Nutrition & Care margin (Q2 2023) | 8.0% | 14 |
| 2024-08-01 | 2024-Q2 | Nutrition & Care margin (Q1 2024) | 15.6% | 14 |
| 2024-08-01 | 2024-Q2 | Net financial debt | 3,611 (EUR in € m) | 14 |
| 2024-08-01 | 2024-Q2 | Net debt (end of June) | €5,186 m | 13 |
| 2024-08-01 | 2024-Q2 | Leverage ratio (Q2 2024) | 1.9x | 14 |
| 2024-08-01 | 2024-Q2 | Leverage ratio (Q1 2024) | 2.1x | 14 |
| 2024-08-01 | 2024-Q2 | H1 FCF | €344 m | 13 |
| 2024-08-01 | 2024-Q2 | Cumulated cost savings expected by end FY 2025 | ~€200 m | 13 |
| 2024-08-01 | 2024-Q2 | Adj. EPS | €0.50 | 13 |
| 2024-08-01 | 2024-Q2 | Adj. EBITDA margin (Q2 2023) | 11.6% | 14 |
| 2024-08-01 | 2024-Q2 | Adj. EBITDA margin (Q1 2024) | 13.8% | 14 |
| 2024-08-01 | 2024-Q2 | Adj. EBITDA margin | 14.7% | 14 |
| 2024-06-26 | 2024-Q1 | ROCE | 3.4% | 12 |
| 2024-06-26 | 2024-Q1 | Leverage | 2.7x | 11 |
| 2024-06-26 | 2024-Q1 | Employees (continuing operations) | 33,090 | 12 |
| 2024-06-26 | 2024-Q1 | Dividend | 1.17 | 12 |
| 2024-06-26 | 2024-Q1 | Cash Conversion Rate | 32% | 12 |
| 2024-06-26 | 2024-Q1 | Adjusted EBITDA Margin | 13.8% | 11 |
| 2024-06-25 | 2024-Q1 | net financial debt leverage | 2.0x | 4 |
| 2024-06-25 | 2024-Q1 | net financial debt leverage | 2.0x | 6 |
| 2024-06-25 | 2024-Q1 | FCF conversion rate | towards 40% | 6 |
| 2024-06-25 | 2024-Q1 | Contingency measures savings | 250 m | 4 |
| 2024-06-25 | 2024-Q1 | cash conversion rate | towards 40% | 4 |
| 2024-06-25 | 2024-Q1 | Adj. EBITDA margin Q3 | 12.9 | 6 |
| 2024-06-25 | 2024-Q1 | ROCE | slightly below 8.3% | 2 |
| 2024-06-25 | 2024-Q1 | Free cash flow conversion rate | 32% | 2 |
| 2024-06-25 | 2024-Q1 | Adj. net debt | €4,555 m | 2 |
| 2024-05-08 | 2024-Q1 | Specialty additives margin Q1 2024 | 20.4% | 10 |
| 2024-05-08 | 2024-Q1 | Specialty additives margin Q1 2023 | 18.2% | 10 |
| 2024-05-08 | 2024-Q1 | Smart materials margin Q1 2024 | 14.5% | 10 |
| 2024-05-08 | 2024-Q1 | Smart materials margin Q1 2023 | 13.8% | 10 |
| 2024-05-08 | 2024-Q1 | Performance materials margin Q1 2024 | 6.7% | 10 |
| 2024-05-08 | 2024-Q1 | Performance materials margin Q1 2023 | 5.2% | 10 |
| 2024-05-08 | 2024-Q1 | Nutrition care margin Q1 2024 | 15.6% | 10 |
| 2024-05-08 | 2024-Q1 | Nutrition care margin Q1 2023 | 8.6% | 10 |
| 2024-05-08 | 2024-Q1 | Net financial debt leverage Q1 2024 | 1.7x | 10 |
| 2024-05-08 | 2024-Q1 | Net financial debt leverage December 2023 | 2.7x | 10 |
| 2024-05-08 | 2024-Q1 | Adj. EBITDA margin Q1 2024 | 13.8% | 10 |
| 2024-05-08 | 2024-Q1 | Adj. EBITDA margin Q1 2023 | 10.2% | 10 |
| 2024-02-26 | FY2023 | Water discharge | 397 million m3 | 9 |
| 2024-02-26 | FY2023 | Vocational training investment | € 64 million | 9 |
| 2024-02-26 | FY2023 | total training investment | € 12 million | 9 |
| 2024-02-26 | FY2023 | total cash outflows for leases | 204 (EUR in € million) | 9 |
| 2024-02-26 | FY2023 | TFS audits initiated | 17 | 9 |
| 2024-02-26 | FY2023 | TFS assessments initiated | 91 | 9 |
| 2024-02-26 | FY2023 | taxonomy eligible turnover 2023 | 17% | 9 |
| 2024-02-26 | FY2023 | taxonomy eligible opex 2023 | 15% | 9 |
| 2024-02-26 | FY2023 | taxonomy eligible capex 2023 | 13% | 9 |
| 2024-02-26 | FY2023 | taxonomy aligned turnover 2023 | 1% | 9 |
| 2024-02-26 | FY2023 | taxonomy aligned opex 2023 | < 1% | 9 |
| 2024-02-26 | FY2023 | taxonomy aligned capex 2023 | < 1% | 9 |
| 2024-02-26 | FY2023 | surface water intake | 153.8 million m3 | 9 |
| 2024-02-26 | FY2023 | sites within 1km of conservation areas | 37% | 9 |
| 2024-02-26 | FY2023 | sites ISO 50001 certified | 57 | 9 |
| 2024-02-26 | FY2023 | scope 3 emissions reduction target 2030 | 11% | 9 |
| 2024-02-26 | FY2023 | scope 1+2 emissions reduction target 2030 | 25% | 9 |
| 2024-02-26 | FY2023 | salt water intake | 179.0 million m3 | 9 |
| 2024-02-26 | FY2023 | return on capital employed | 3.4 percent | 9 |
| 2024-02-26 | FY2023 | renewable electricity percentage | 35% | 9 |
| 2024-02-26 | FY2023 | recycled water and rainwater | 4.7 million m3 | 9 |
| 2024-02-26 | FY2023 | property, plant & equipment | 6,294 (in € million) | 9 |
| 2024-02-26 | FY2023 | production volume 2022 | 8.38 million metric tons | 9 |
| 2024-02-26 | FY2023 | production volume | 7.50 million metric tons | 9 |
| 2024-02-26 | FY2023 | process safety incident rate | 0.43 | 9 |
| 2024-02-26 | FY2023 | occupational health performance index target | ≥ 5.0 | 9 |
| 2024-02-26 | FY2023 | new suppliers evaluated | 1,548 | 9 |
| 2024-02-26 | FY2023 | maximum default risk venture capital | 71 (EUR in € million) | 9 |
| 2024-02-26 | FY2023 | maximum default risk simplified model | 1,263 (in € million) | 9 |
| 2024-02-26 | FY2023 | major raw material suppliers validated | 67% | 9 |
| 2024-02-26 | FY2023 | lost time injury rate | below 0.26 | 9 |
| 2024-02-26 | FY2023 | lease liabilities | 937 (in € million) | 9 |
| 2024-02-26 | FY2023 | interest expense leases | 17 (EUR in € million) | 9 |
| 2024-02-26 | FY2023 | indirect procurement TFS coverage | 70% | 9 |
| 2024-02-26 | FY2023 | impairment loss recognized | 475 (in € million) | 9 |
| 2024-02-26 | FY2023 | high risk water sites 2030 | 19 | 9 |
| 2024-02-26 | FY2023 | high or very high risk water sites 2050 | 26 | 9 |
| 2024-02-26 | FY2023 | groundwater intake | 46.7 million m3 | 9 |
| 2024-02-26 | FY2023 | GHG emissions scope 3 2023 | 19.2 million metric tons | 9 |
| 2024-02-26 | FY2023 | GHG emissions scope 2 2023 | 1.5 million metric tons | 9 |
| 2024-02-26 | FY2023 | GHG emissions scope 1 2023 | 3.8 million metric tons | 9 |
| 2024-02-26 | FY2023 | freshwater intake reduction target 2030 | 3% | 9 |
| 2024-02-26 | FY2023 | fair value plan assets | 7,155 (EUR in € million) | 9 |
| 2024-02-26 | FY2023 | facilities with renewable energy | 50 | 9 |
| 2024-02-26 | FY2023 | variable lease payment expenses | 3 (EUR in € million) | 9 |
| 2024-02-26 | FY2023 | short-term lease expenses | 17 (EUR in € million) | 9 |
| 2024-02-26 | FY2023 | low-value asset expenses | 3 (EUR in € million) | 9 |
| 2024-02-26 | FY2023 | Evonik Learning Community members | 16,500 | 9 |
| 2024-02-26 | FY2023 | Evonik Explorer Program participants | 320 | 9 |
| 2024-02-26 | FY2023 | EU ETS facilities | 26 | 9 |
| 2024-02-26 | FY2023 | EU ETS emissions 2023 | 2.5 million metric tons CO2 | 9 |
| 2024-02-26 | FY2023 | EcoVadis gold rating consecutive years | 7 | 9 |
| 2024-02-26 | FY2023 | drinking water intake | 19.0 million m3 | 9 |
| 2024-02-26 | FY2023 | direct procurement TFS coverage | 80% | 9 |
| 2024-02-26 | FY2023 | corporate venture capital holdings | 42 (in € million) | 9 |
| 2024-02-26 | FY2023 | contractor accidents | 48 | 9 |
| 2024-02-26 | FY2023 | cash conversion rate | 48 percent | 9 |
| 2024-02-26 | FY2023 | Capex | 793 million | 9 |
| 2024-02-26 | FY2023 | apprentices trained | 1,600 | 9 |
| 2024-02-26 | FY2023 | apprentices total | 1,112 | 9 |
| 2024-02-26 | FY2023 | absolute FCF | 801 million | 9 |
| 2024-02-26 | FY2023 | transaction prices of unsatisfied performance obligations (up to 1 year) | 923 (in € million) | 9 |
| 2024-02-26 | FY2023 | transaction prices of unsatisfied performance obligations (total) 2022 | 4,270 (in € million) | 9 |
| 2024-02-26 | FY2023 | Transaction prices of unsatisfied performance obligations (more than 5 years) | 2,158 (in € million) | 9 |
| 2024-02-26 | FY2023 | Transaction prices of unsatisfied performance obligations (more than 3 and up to 5 years) | 581 (in € million) | 9 |
| 2024-02-26 | FY2023 | Transaction prices of unsatisfied performance obligations (more than 1 and up to 3 years) | 654 (in € million) | 9 |
| 2024-02-26 | FY2023 | Total turnover (%) | 6.6 | 9 |
| 2024-02-26 | FY2023 | Sales from Next Generation Solutions | 43 | 9 |
| 2024-02-26 | FY2023 | ROCE | 8.3 | 9 |
| 2024-02-26 | FY2023 | R&D expenses ratio | 2.9 | 9 |
| 2024-02-26 | FY2023 | Personnel expense as % of sales | 21.3 (EUR millions) | 9 |
| 2024-02-26 | FY2023 | PSI-R (Process safety incident rate) | 0.43 | 9 |
| 2024-02-26 | FY2023 | New hires under 30 (%) | 47 | 9 |
| 2024-02-26 | FY2023 | New hires over 50 (%) | 7 | 9 |
| 2024-02-26 | FY2023 | New hires aged 30 to 50 (%) | 46 | 9 |
| 2024-02-26 | FY2023 | Nationalities represented | 109 | 9 |
| 2024-02-26 | FY2023 | Mobile working maximum average (%) | 60 | 9 |
| 2024-02-26 | FY2023 | LTI-R (Lost time injury rate) | 0.21 | 9 |
| 2024-02-26 | FY2023 | Equity ratio as of December 31 (2022) | 50.7 | 9 |
| 2024-02-26 | FY2023 | Equity ratio as of December 31 | 41.1 | 9 |
| 2024-02-26 | FY2023 | Equity ratio | 45.1 | 9 |
| 2024-02-26 | FY2023 | Early turnover rate (%) | 2.2 | 9 |
| 2024-02-26 | FY2023 | Cash conversion rate | 48 | 9 |
| 2024-02-26 | FY2023 | Average length of service (years) | 13.9 | 9 |
| 2024-02-26 | FY2023 | Apprentices/trainees | 1,150 | 9 |
| 2024-02-26 | FY2023 | Adjusted EBITDA margin | 10.8 | 9 |
| 2024-03-04 | 2023-Q4 | Dividend | 1.17 | 8 |
| 2024-03-04 | 2023-Q4 | cash conversion rate | 48% | 8 |
| 2024-03-04 | 2023-Q4 | Adj. net debt | 4,918 (EUR in € m) | 8 |
| 2024-03-04 | 2023-Q4 | ROCE | 3.4% | 7 |
| 2024-03-04 | 2023-Q4 | Leverage | 3.0x | 7 |
| 2024-03-04 | 2023-Q4 | Dividend per share | €1.17 | 7 |
| 2023-11-07 | 2023-Q3 | Leverage (net debt / Adj. EBITDA) | 2.7x | 5 |
| 2023-11-07 | 2023-Q3 | Adjusted EBITDA Margin (%) | 12.9 | 5 |
| 2023-08-10 | 2023-Q2 | Specialty Additives Adj. EBITDA Margin | 22.0% | 3 |
| 2023-08-10 | 2023-Q2 | Smart Materials Adj. EBITDA Margin | 10.9% | 3 |
| 2023-08-10 | 2023-Q2 | Performance Materials Adj. EBITDA Margin | 6.5% | 3 |
| 2023-08-10 | 2023-Q2 | Nutrition & Care Adj. EBITDA Margin | 8.0% | 3 |
| 2023-08-10 | 2023-Q2 | Net financial debt leverage | 2.0x | 3 |
| 2023-08-10 | 2023-Q2 | Leverage (net debt / Adj. EBITDA) | 2.9x | 3 |
| 2023-08-10 | 2023-Q2 | Cash conversion rate target | 40% | 3 |
| 2023-08-10 | 2023-Q2 | Adjusted EBITDA Margin (Q2 2022) | 15.3% | 3 |
| 2023-08-10 | 2023-Q2 | Adjusted EBITDA Margin (Q1 2023) | 10.2% | 3 |
| 2023-08-10 | 2023-Q2 | Adjusted EBITDA Margin | 11.6% | 3 |
| 2023-05-09 | 2023-Q1 | Low net financial debt leverage | 1.4x | 1 |
| 2023-05-09 | 2023-Q1 | Leverage (net debt / Adj. EBITDA) | 2.1x | 1 |
Advertisement
Guidance Tracking (latest per metric/period · 19/38)#
All management forecasts (guidance) and their later outcome. Methodology
Actuals: revenue in €m · EPS in € per share
| For period | Guided on | Metric | Guided | Actual | Verdict | Direction | Source |
|---|---|---|---|---|---|---|---|
| FY2026 | 2026-08-04 | Revenue | 15,000 | – | pending | raised | 29 |
| FY2026 | 2026-08-04 | Tax rate | ~25% | – | pending | cut | 29 |
| FY2026 | 2026-08-04 | EBITDA (adjusted) | 2,000–2,200 | – | pending | raised | 29 |
| FY2026 | 2026-07-15 | EPS (non-GAAP) | 1.54 | – | pending | initiated | 33 |
| FY2026 | 2026-05-08 | Free Cash Flow Conversion Rate | ~40% | – | pending | initiated | 28 |
| FY2026 | 2026-05-08 | ROCE | 6.1% | – | pending | – | 28 |
| FY2026 | 2026-03-04 | Capex | ~750 | – | pending | confirmed | 31 |
| FY2026 | 2026-03-04 | Free Cash Flow | ~40% | – | pending | confirmed | 29 |
| 2026-Q2 | 2026-07-15 ° | Revenue | 3,741 | 3,893 | beat | initiated | 33 |
| 2026-Q2 | 2026-07-15 ° | EPS (non-GAAP) | 0.51 | 0.65 | beat | initiated | 33 |
| 2026-Q2 | 2026-07-15 ° | EBITDA (adjusted) | 621 | 630 | beat | initiated | 33 |
| FY2025 | 2025-11-03 | EBITDA (adjusted) | 1,900 | 1,874 | miss | confirmed | 24 |
| FY2025 | 2025-11-03 | fcf_reported | 30–40% | – | – | confirmed | 24 |
| FY2025 | 2025-08-01 | Revenue | 14,000–15,000 | 14,069 | in line | confirmed | 24 |
| FY2025 | 2025-08-01 | Capex | ~750 | 748 | miss | cut | 24 |
| FY2025 | 2025-08-01 | fcf | ~40% | – | – | confirmed | 21 |
| FY2025 | 2025-05-12 | Free Cash Flow | ~40% | – | – | confirmed | 18 |
| FY2025 | 2025-03-05 | Free Cash Flow conversion | ~40% | – | – | confirmed | 17 |
| 2025-Q1 | 2025-03-05 | EBITDA (adjusted) | above prior-year level | 560 | – | initiated | 17 |
| FY2024 | 2024-11-06 | EBITDA (adjusted) | considerably above prior-year level | 2,065 | – | raised | 15 |
| FY2024 | 2024-05-08 | Free Cash Flow conversion rate | ~40% | – | – | confirmed | 16 |
| FY2024 | 2024-05-08 | Adj. D&A | 1,000 | – | – | initiated | 10 |
| FY2024 | 2024-03-04 | Tax rate | ~30% | – | – | initiated | 10 |
| FY2024 | 2024-03-04 | Capex | 750 | 840 | beat | confirmed | 14 |
| FY2024 | 2024-03-04 | fcf_reported | ~40% | – | – | confirmed | 15 |
| FY2024 | 2024-03-04 | Free Cash Flow conversion | 40% | – | – | confirmed | 14 |
| FY2024 | 2024-02-26 | Revenue | 15,000–17,000 | 15,157 | in line | confirmed | 15 |
| FY2024 | 2024-02-26 | Cash outflows for investments in intangible assets, property, plant and equipment | 750 | – | – | initiated | 9 |
| FY2024 | 2024-02-26 | Free cash flow: cash conversion rate | 40% | – | – | initiated | 9 |
| 2024-Q3 | 2024-08-01 | EBITDA (adjusted) | -578–2 | -8 | – | confirmed | 13 |
| 2024-Q2 | 2024-05-08 | EBITDA (adjusted) | 522 | 578 | beat | confirmed | 11 |
| 2024-Q1 | 2024-03-04 | EBITDA (adjusted) | above prior-year level | 522 | – | initiated | 8 |
| FY2023 | 2024-06-25 ° | Revenue | 17,000–19,000 | 15,267 | miss | raised | 2 |
| FY2023 | 2024-06-25 ° | Capex | 900 | 793 | miss | raised | 2 |
| FY2023 | 2024-06-25 ° | EBITDA (adjusted) | 2,100–2,400 | 1,656 | miss | raised | 2 |
| FY2023 | 2024-06-25 ° | Free cash flow conversion | 40% | – | – | confirmed | 6 |
| FY2023 | 2023-11-07 | FCF | 40% | – | – | confirmed | 5 |
| FY2023 | 2023-05-09 | fcf_reported | 40% | – | – | – | 1 |
Advertisement
Development#
A condensed summary per reporting period as running text: what changed operationally, which drivers management names, how earnings and cash flow developed. Methodology
FY2026
In fiscal year 2026, Evonik Industries AG generated revenue of – million and reported adjusted EPS of – 32. First-quarter revenue was 3,427 million, with sales down 9% year-over-year as a 5% currency headwind and a 3% organic decline weighed on results; adjusted EBITDA of €475 million slightly exceeded expectations, supported by a late-March volume uptick 26. Second-quarter revenue rose to 3,893 million, with sales up 11% year-over-year on higher volumes and prices; adjusted EBITDA of €630 million came in ahead of expectations, primarily driven by strong Advanced Technologies segment performance, and H1 free cash flow of €232 million improved significantly from €16 million in H1 2025 29. Following the second-quarter beat, Evonik raised its full-year adjusted EBITDA outlook considerably to €2.0-2.2 billion and lifted its sales guidance to around €15 billion, while extending the Evonik Tailor Made efficiency programme through 2029 targeting an additional 3,200 FTE reductions 29 31.
FY2025
Full-year revenue totaled 14,069 million, weighed down by FX headwinds, non-core divestitures, and weaker industrial demand that intensified through the middle quarters of the year 136 21 24. Adjusted EBITDA reached approximately €1,874 million for FY2025, meeting the revised full-year guidance of approximately €1.9 billion issued in Q3 25. The full-year operating result was a loss of 420 million 136, burdened in part by a €170 million impairment charge on the Oxeno C4 business recorded in Q3 24. Full-year free cash flow amounted to 695 million 136, supported by a strong Q4 recovery driven by decisive net working capital management 25. Net financial debt stood at 3,670 million at year-end 136, and Evonik introduced a new dividend policy of €1 per share for fiscal 2025 alongside a 40-60% payout ratio for subsequent years 25.
FY2024
Evonik Industries AG generated full-year 2024 revenue of 15,157 million euros and reported adjusted EBITDA of €2,065 million, up 25% year-over-year with broad-based growth across all divisions 17. Free cash flow reached 873 million euros in FY 2024, corresponding to a 42% cash conversion rate, well ahead of the prior year 17. The company launched the Evonik Tailor Made reorganization program in Q1 2024 targeting €400 million in savings, and completed the divestiture of the Superabsorbers business on August 31, 2024 15. Net debt at year-end stood at 3,735 million euros, while the dividend was maintained at €1.17 per share for FY 2024 17. A new two-segment group structure with Custom Solutions and Advanced Technologies was announced, set to take effect in Q2 2025 17.
FY2023
Evonik Industries AG reported group sales of EUR 15,267 million in FY2023, down 17% year-over-year as volumes declined across most divisions and selling prices fell, particularly in Animal Nutrition and Performance Intermediates 9. Adjusted EBITDA fell 33% to €1,656 million, with the adjusted EBITDA margin declining to 10.8%, finishing within the revised guidance range of €1.6 to 1.8 billion despite €50 million in exceptional headwinds in Q4 7 9. The group recorded a net loss of EUR 452 million compared to net income of €540 million in the prior year, primarily driven by impairment losses totaling €736 million on assets including Animal Nutrition facilities and Silica 9. Free cash flow of EUR 801 million was broadly stable year-over-year with a record cash conversion rate of 48%, supported by improved net working capital management and disciplined capital spending 9. In response, Evonik executed a €250 million contingency savings program, divested the Lülsdorf site, and launched the Evonik Tailor Made reorganization targeting an additional €400 million in savings by end-2026 8 9.
Advertisement
Glossary#
- Revenue: Revenue from contracts with customers, net of sales deductions, as the company itself reports it; not total output, gross revenue, GMV or order intake.
- Op. income: The operating line of the income statement; EBIT only as a marked fallback, never pre-tax or ordinary income.
- Op. income (adj.): Adjusted operating income, verbatim and company-defined (non-GAAP), never derived.
- EBITDA (adj.): Adjusted EBITDA, verbatim and company-defined (non-GAAP), never derived.
- Net income: Net income attributable to the shareholders of the parent, after discontinued operations; not the result including minority interests, not comprehensive income.
- EPS: Diluted earnings per share attributable to the shareholders of the parent; a printed figure always beats a calculated one, calculated values are marked.
- EPS adj.: Adjusted earnings per share, verbatim and company-defined (non-GAAP).
- FCF: Free cash flow = operating cash flow minus capital expenditure on property, plant and equipment; the company's own free cash flow figure is shown separately.
- OCF: Cash flow from operating activities as reported; IFRS companies may show interest paid in financing cash flow, so the figure is not always comparable.
- Cash: Cash and cash equivalents, without securities unless the company reports them as part of the position.
- Net Debt: Net debt = financial debt excluding lease liabilities minus cash at the same reporting date; the company's own net position may differ.
- *: derived, the formula is in the hover
- ≈: calculated, approximation
- ~: uncertain; the value stays visible, verdicts do not use it
- °: repaired by a targeted query against the document, or curated with documentary evidence
- EBIT: EBIT as a fallback: the income statement carries no operating line
- basic: basic earnings per share as a fallback when diluted is missing
Advertisement
Sources: quarterly reports, annual reports and investor relations documents#
All original documents NadirAlpha used for this report, with type (quarterly report, half-year report, annual report, earnings release), publication date and a direct link to the filing (EDINET/SEC/IR). Methodology
47 documents · 2023 to 2026 · IR
| # | Document type | Published | Link |
|---|---|---|---|
| #34 | IR-Quarter quarterly report | – | Open |
| #35 | IR-Quarter quarterly report | – | Open |
| #36 | IR-Quarter quarterly report | – | Open |
| #37 | IR-Quarter quarterly report | – | Open |
| #40 | IR-Quarter quarterly report | – | Open |
| #44 | IR-Quarter quarterly report | – | Open |
| #1 | IR-Quarter quarterly report | 2023-05-09 | Open |
| #3 | IR-Quarter quarterly report | 2023-08-10 | Open |
| #5 | IR-Quarter quarterly report | 2023-11-07 | Open |
| #9 / #109 | IR-Report report | 2024-02-26 | Open |
| #7 | IR-Quarter quarterly report | 2024-03-04 | Open |
| #8 / #108 | IR-Quarter quarterly report | 2024-03-04 | Open |
| #10 | IR-Quarter quarterly report | 2024-05-08 | Open |
| #2 / #102 | IR-Quarter quarterly report | 2024-06-25 | Open |
| #4 / #104 | IR-Quarter quarterly report | 2024-06-25 | Open |
| #6 / #106 | IR-Quarter quarterly report | 2024-06-25 | Open |
| #11 | IR-Quarter quarterly report | 2024-06-26 | Open |
| #12 / #114 | IR-Quarter quarterly report | 2024-06-26 | Open |
| #41 | IR-Quarter quarterly report | 2024-06-26 | Open |
| #13 | IR-Quarter quarterly report | 2024-08-01 | Open |
| #14 / #116 | IR-Quarter quarterly report | 2024-08-01 | Open |
| #38 | IR-Quarter quarterly report | 2024-08-04 | Open |
| #15 | IR-Quarter quarterly report | 2024-11-06 | Open |
| #16 / #118 | IR-Quarter quarterly report | 2024-11-06 | Open |
| #39 | IR-Quarter quarterly report | 2024-11-06 | Open |
| #17 / #119 | IR-Quarter quarterly report | 2025-03-05 | Open |
| #19 / #123 | IR-Quarter quarterly report | 2025-05-09 | Open |
| #18 | IR-Quarter quarterly report | 2025-05-12 | Open |
| #20 / #124 | IR-Quarter quarterly report | 2025-05-12 | Open |
| #45 | IR-Quarter quarterly report | 2025-07-14 | Open |
| #21 | IR-Quarter quarterly report | 2025-08-01 | Open |
| #22 / #126 | IR-Quarter quarterly report | 2025-08-01 | Open |
| #42 | IR-Quarter quarterly report | 2025-08-01 | Open |
| #23 | IR-Quarter quarterly report | 2025-11-03 | Open |
| #24 / #128 | IR-Quarter quarterly report | 2025-11-04 | Open |
| #43 | IR-Quarter quarterly report | 2025-11-04 | Open |
| #25 / #129 | IR-Quarter quarterly report | 2026-03-04 | Open |
| #32 | IR-Quarter quarterly report | 2026-03-23 | Open |
| #27 | IR-Quarter quarterly report | 2026-05-07 | Open |
| #26 | IR-Quarter quarterly report | 2026-05-08 | Open |
| #28 / #134 | IR-Quarter quarterly report | 2026-05-08 | Open |
| #46 | IR-Quarter quarterly report | 2026-05-08 | Open |
| #33 | IR-Quarter quarterly report | 2026-07-15 | Open |
| #47 | IR-Quarter quarterly report | 2026-08-03 | Open |
| #29 | IR-Quarter quarterly report | 2026-08-04 | Open |
| #30 / #136 | IR-Quarter quarterly report | 2026-08-04 | Open |
| #31 / #137 | IR-Quarter quarterly report | 2026-08-04 | Open |
FAQ#
Is there a management forecast (guidance) for FY2026?
Yes. Management has issued targets for FY2026, including Revenue. The guidance tracking chapter shows all targets and checks them against the actuals reported later; neutral, with no estimate of our own.
Which additional key figures does Evonik Industries AG report?
As reported for Q2 2026: ROCE, Leverage, Cash Conversion Rate, Dividend, Sales share with Next Generation Solutions, Employees (continuing operations). The chapter Reported KPIs lists every value with its source. Revenue is broken down by Infrastructure (incl. C4 business) / Other, Additives, Inorganics, Care.
Does Evonik Industries AG pay a dividend?
The filings report on the dividend; most recent entry: dividends paid 1.00 € (2026-Q2) (as reported, no assessment of our own). Details with source links are in the report chapters.
Where can I find the official investor relations documents of Evonik Industries AG?
NadirAlpha links all 64 original filings used (IR documents) in the sources chapter: quarterly report, report, each with type, publication date and a direct link; every figure in the report carries a source number.
More reports by NadirAlpha#
Recently updated
Same sector and country
Advertisement